What obstructive sleep apnea is and why screening exists

Obstructive sleep apnea (OSA) is a disorder in which the upper airway repeatedly narrows or collapses during sleep, causing breathing reductions (hypopneas) or pauses (apneas), sleep fragmentation, intermittent hypoxia, and sympathetic activation. Clinically, it overlaps with loud snoring, witnessed breathing pauses, choking or gasping, non-restorative sleep, and excessive daytime sleepiness. Untreated OSA is associated with hypertension, atrial fibrillation, heart failure, stroke risk, metabolic dysfunction, cognitive impairment, and motor vehicle risk in susceptible individuals. Because many patients do not volunteer a complete sleep history, brief, validated questionnaires help stratify pretest probability and identify who may benefit from objective sleep testing or specialist referral.

The STOP-BANG instrument is one of the most widely used OSA screening tools. It compresses key clinical risk factors into a mnemonic that is easy to remember in primary care, preoperative clinics, cardiology, endocrinology, and sleep medicine workflows. It is intended as a screening aid: it raises or lowers suspicion and supports triage; it does not replace polysomnography or other standardized sleep studies when diagnosis or severity grading is required.

Structure of the STOP-BANG score

STOP-BANG includes eight binary items. Traditionally, each item answered “yes” contributes one point, for a total score ranging from 0 to 8. The first four letters (STOP) capture symptom and blood-pressure features often elicited from history; the last four (BANG) capture anthropometric and demographic risk modifiers that are frequently associated with higher apnea–hypopnea burden in population studies.

S — Snoring

Snoring arises from turbulent airflow and vibration of the upper airway soft tissues during sleep. Not everyone who snores has OSA, but loud, habitual snoring is a common harbinger of increased collapsibility of the pharyngeal airway. Screening instruments typically define a positive snoring item when snoring is loud enough to disturb a bed partner or to be heard through a closed door, or when it is described as louder than normal talking. Clinicians should distinguish benign snoring from snoring accompanied by witnessed apneas, choking, or pronounced daytime sleepiness, which increases concern for OSA. Nasal obstruction, alcohol, sedatives, and supine sleep can intensify snoring intensity and may influence both symptoms and perception by bed partners.

T — Tired, fatigued, or sleepy during the daytime

This item targets daytime sequelae of disrupted sleep: sleepiness, fatigue, impaired concentration, or a sense of non-restorative sleep. OSA fragments sleep architecture and produces recurrent arousals that may not be recalled, so patients may report fatigue more prominently than classic “sleep attacks.” Conversely, sleepiness is not specific to OSA; insufficient sleep duration, shift work, depression, medication effects, restless legs, narcolepsy, and other conditions can mimic or coexist. When the tiredness item is positive, the history should explore sleep schedule, nap behavior, drowsy driving, and safety-sensitive occupations. Integration with other STOP-BANG features and, when appropriate, objective testing helps clarify whether OSA is a likely contributor.

O — Observed apnea (witnessed breathing pauses)

A bed partner or household member may observe breathing pauses, gasping, choking, or snoring crescendos followed by silence. Witnessed apneas are among the more specific historical clues for OSA because they directly suggest recurrent upper-airway closure. Some patients sleep alone or have unreliable observers; a negative answer therefore does not exclude disease. In contrast, a clear witnessed-apnea history often justifies a lower threshold for sleep testing, especially when combined with hypertension, obesity, or cardiovascular comorbidity.

P — Pressure (hypertension or treatment for high blood pressure)

OSA and hypertension frequently travel together through pathways that include sympathetic surges, endothelial stress, fluid shifts, and renin–angiotensin activation. A positive blood-pressure item may reflect diagnosed hypertension, repeated elevated clinic readings, home or ambulatory patterns consistent with hypertension, or pharmacologic treatment aimed at blood pressure control. This item underscores that OSA evaluation is not purely “sleep comfort” care; it intersects with cardiovascular prevention and may influence choices about antihypertensive intensity, arrhythmia surveillance, and perioperative risk discussions.

B — Body mass index greater than 35 kg/m²

Higher adiposity, especially central adiposity, increases soft-tissue bulk around the upper airway and can reduce pharyngeal patency and lung volume during sleep, promoting collapse. A BMI threshold above 35 kg/m² identifies a group at markedly elevated OSA prevalence in many cohorts. BMI is an imperfect proxy for fat distribution—some patients with lower BMI still have significant OSA due to craniofacial anatomy, tonsillar hypertrophy, or muscle tone effects—so clinical judgment remains essential.

A — Age greater than 50 years

OSA prevalence rises with age in adults, reflecting changes in airway compliance, weight trajectory, and comorbidity burden, among other factors. The age item improves discrimination in screening populations by capturing risk that may be underrepresented if one relied only on self-reported sleepiness, which can be blunted or masked in older adults or attributed to other chronic conditions.

N — Neck circumference greater than 40 cm

Neck size serves as a practical surrogate for upper-airway soft-tissue volume and is measured with a tape at a standardized level (commonly near the cricothyroid membrane) with the neck neutral. Values above roughly 40 cm (about 16 inches) correlate with higher OSA likelihood in many validation studies. Measurement technique matters: overly loose tape placement or postural neck flexion can skew results. Some protocols have explored sex-specific neck thresholds; if your institution uses a modified cutoff, document that consistently so scores remain comparable across visits.

G — Gender male (per the original questionnaire)

In adult populations, male sex is associated with higher OSA prevalence in multiple epidemiologic datasets, related to differences in fat distribution, airway anatomy, and hormonal influences, among other contributors. The screening mnemonic retains a binary gender item consistent with the original instrument’s validation framing. Clinicians should interpret this item thoughtfully in individual patients: OSA remains common in women, and presentations may differ (for example, less classic snoring history or greater insomnia complaints), so a low STOP-BANG score should not dismiss suspicion when symptoms or comorbidities suggest otherwise.

How totals are usually interpreted in practice

Because STOP-BANG is a risk stratification tool, numeric cutoffs summarize pretest probability rather than diagnosing disease. In many clinical summaries, scores of 0–2 are described as lower-risk in general screening contexts, 3–4 as intermediate, and 5–8 as high risk for clinically important OSA—particularly moderate-to-severe disease in several validation cohorts. Intermediate scores often prompt a structured sleep history, examination of the upper airway when relevant, assessment of comorbidities, and a shared decision about home sleep apnea testing or polysomnography. Higher scores frequently justify expedited evaluation when symptoms, occupation (commercial driving), or perioperative planning amplify stakes.

Exact predictive values depend on the population studied (sleep clinic versus surgical preoperative clinic versus community screen) and the definition of OSA (apnea–hypopnea index thresholds and scoring rules). For perioperative pathways, institutions sometimes pair STOP-BANG with protocolized escalation to reduce unrecognized OSA before anesthesia and opioids. In primary care, the same score may primarily trigger cardiovascular risk refinement and lifestyle counseling about weight, alcohol, and sleep position.

Strengths, limitations, and how to use the score responsibly

STOP-BANG’s strengths include brevity, ease of administration without specialized equipment (aside from a tape measure for neck circumference and height/weight for BMI), and alignment with features clinicians already collect. It performs well as a triage filter across diverse settings when the goal is to identify individuals who warrant further evaluation.

Limitations deserve equal emphasis. Questionnaire-based tools are sensitive to language, health literacy, and cultural factors affecting symptom reporting. Patients may underreport snoring or apnea events if they sleep alone. Sleepiness scales and single-item proxies do not capture the full spectrum of neurobehavioral impairment. BMI and neck circumference do not fully represent airway anatomy; craniofacial disorders, acromegaly, tonsillar enlargement, and nasal obstruction can predispose to OSA without extreme BMI. Finally, STOP-BANG does not determine optimal therapy—continuous positive airway pressure, oral appliances, weight loss, positional therapy, and surgery are chosen after diagnosis, severity assessment, comorbidity review, and patient preference.

Responsible use means treating STOP-BANG as one data layer in a broader assessment: corroborate with examination, comorbid conditions, medication effects, and, when indicated, objective sleep testing. The CalcMD calculator on this page helps you sum items and visualize the contribution of each domain for teaching and shared decision-making; it is not a substitute for individualized medical advice from a licensed clinician or sleep specialist.